Intellia Therapeutics
NTLA
301 hedge funds and large institutions have $3.44B invested in Intellia Therapeutics in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 120 increasing their positions, 94 reducing their positions, and 67 closing their positions.
36% more capital inflows, than outflows
Capital inflows: $390M | Capital outflows: $286M
28% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 94
1.98% more ownership
Funds ownership: 87.17% → 89.14% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
14% less funds holding
Funds holding: 350 → 301 (-49)
37% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $49M
66% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$40.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$37.9M |
| 3 |
Avidity Partners Management
Dallas,
Texas
|
+$37.3M |
| 4 |
ARK Investment Management
St. Petersburg,
Florida
|
+$27.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$28.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$25.4M |
| 3 |
Jennison Associates
New York
|
-$22.5M |
| 4 |
DVF
Discovery Value Fund
Singapore
|
-$20.4M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$17.5M |
NTLA Hedge Fund Activity: Q2 2022 in Review
301 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2022, worth a combined $3.44B — down 27% from $4.71B a quarter earlier.
Sellers outnumbered buyers: 67 funds closed out of NTLA and 23 opened new positions — a net loss of 44 holders — while 94 trimmed existing stakes and 120 added.
The largest buyer was Federated Hermes, adding an estimated $40.6M. The largest seller was Victory Capital Management, cutting an estimated $28.4M.
- 301 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2022, down from 350 in Q1 2022.
- Funds reported $3.44B of Intellia Therapeutics stock for Q2 2022, down 27% quarter-over-quarter.
- 23 funds opened new Intellia Therapeutics positions in Q2 2022 and 67 closed out, a net change of -44 holders.
- The largest Intellia Therapeutics buyer in Q2 2022 was Federated Hermes, an estimated $40.6M added.
- The largest Intellia Therapeutics seller in Q2 2022 was Victory Capital Management, an estimated $28.4M sold.
Based on aggregated 13F filings for Q2 2022.